A carregar...
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study
BACKGROUND: Psoriasis can greatly impact patients’ lives by influencing clothing worn as well as by impairing sexual functioning. Secukinumab, a human monoclonal antibody selectively neutralizing interleukin‐17A, has demonstrated good efficacy and safety in the treatment of moderate‐to‐severe psoria...
Na minha lista:
| Publicado no: | J Eur Acad Dermatol Venereol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6084293/ https://ncbi.nlm.nih.gov/pubmed/28602039 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.14391 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|